Disregulation of proopiomelanocortin and contagious maladaptive behavior

Sato, 1997, Subregional assignment of the proopiomelanocortin gene (POMC) to human chromosome band 2p23.3 by fluorescence in situ hybridization, Cytogenet. Cell Genet., 76, 221, 10.1159/000134554 Seidah, 1992, Proprotein and prohormone convertases of the subtilisin family, Trends Endocrinol. Metab., 3, 133, 10.1016/1043-2760(92)90102-7 Mains, 1999, Peptides, 363 Mains, 1997, PACE4: a subtilisin-like endoprotease with unique properties, Biochem. J., 321, 587, 10.1042/bj3210587 Seidad, 1991, Cloning and primary sequence of a mouse candidate prohormone convertase PC1 homologous to PC2, Furin, KEX 2: distinct chromosomal localization and messenger RNA distribution in brain and pituitary compared to PC2, Mol. Endocrinol., 5, 111, 10.1210/mend-5-1-111 Bertagna, 1994, Proopiomelanocortin-derived peptides, Endocrinol. Metab. Clin. N. Am., 23, 467, 10.1016/S0889-8529(18)30079-3 Boutillier, 1995, Corticotropin-releasing hormone stimulates proopiomelanocortin transcription by cFos-dependent and -independent pathways: characterization of an AP1 site in exon 1, Mol. Endocrinol., 9, 745, 10.1210/me.9.6.745 Zheng, 1994, The development expression in rat proteases furin, PC1, PC2, and carboxypeptidase E: implications for early maturation of proteolytic processing capacity, J. Neurosci., 14, 4656, 10.1523/JNEUROSCI.14-08-04656.1994 Bertagna, 1994, Proopiomelanocortin-derived peptides, Endocrinol. Metab. Clin. N. Am., 23, 467, 10.1016/S0889-8529(18)30079-3 Strand, 1999 Sandman, 1987, Behavior actions of ACTH and related peptides, 147 Sandman, 1986, Persisting subsensitivity of the striatal dopamine system after fetal exposure to B-endorphin, Life Sci., 39, 1755, 10.1016/0024-3205(86)90095-0 Beckwith, 1976, The influence of neonatal injections of a-MSH on learning, memory and attention in rats, Physiol. Behav., 18, 63, 10.1016/0031-9384(77)90095-6 Sandman, 1997, Dissociation of POMC peptides after self-injury predicts response to centrally acting opiate blockers, Am. J. Ment. Retard., 102, 182, 10.1352/0895-8017(1997)102<0182:DOPPAS>2.0.CO;2 Sandman, 1999, Proopiomelanocortin (POMC) disregulation and response to opiate blockers, Ment. Retard. Dev. Disabil. Res. Rev., 5, 314, 10.1002/(SICI)1098-2779(1999)5:4<314::AID-MRDD9>3.0.CO;2-G Carr, 1994, Emerging themes in the functional analysis of problem behavior, J. Appl. Behav. Anal., 27, 393, 10.1901/jaba.1994.27-393 Bouvard, 1995, Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study, Psychiatry Res., 58, 191, 10.1016/0165-1781(95)02601-R Ernst, 1993, Plasma beta-endorphin levels, naltrexone and haloperidol in autistic children, Psychopharmacology Bulletin, 29, 221 Gillberg, 1995, Endogenous opioids and opiate antagonists in autism: brief review of empirical findings and implications for clinicians, Dev. Med. Child Neurol., 37, 88 LeBoyer, 1994, Difference between plasma N- and C- terminally directed beta-endorphin immunoreactivity in infantile autism, Am. J. Psychiatry, 151, 1797, 10.1176/ajp.151.12.1797 Leboyer, 1999, Whole blood serotinin and plasma beta-endorphin in autistic probands and their first degree relatives, Soc. Biol. Psychiatry, 45, 158, 10.1016/S0006-3223(97)00532-5 Sandman, 1990, An orally administered opiate blocker, Naltrexone attenuates self-injurious behavior, Am. J. Ment. Retard., 95, 93 Sandman, 1990, Opiod peptides and development: clinical implications, Ann. N.Y. Acad. Sci., 579, 91, 10.1111/j.1749-6632.1990.tb48353.x Sandman, 2000, Uncoupling of proopiomelanocortin (POMC) fragments is related to self-injury, Peptides, 21, 785, 10.1016/S0196-9781(00)00209-6 Sandman, 2002, Opiods and the maintenance of self-injurious behavior, 191 Sandman, 1995, Opiate mechanisms in self-injury, Ment. Retard. Dev. Disabil. Res. Rev., 1, 130, 10.1002/mrdd.1410010209 Krude, 1998, Severe early-onset obesity, adrenal insufficient and red hair pigmentation caused by POMC mutations in humans, Nat. Genet., 19, 155, 10.1038/509 Cazzullo, 1999, Beta-endorphin levels in peripheral blood mononuclear cells and long-term naltrexone treatment in autistic children, Eur. Neuropsycholopharmacol., 9, 361, 10.1016/S0924-977X(99)00010-3 Crews, 1999, Cessation of long-term naltrexone administration: longitudinal follow-ups, Res. Dev. Disabil., 20, 23, 10.1016/S0891-4222(98)00029-8 Sandman, 1993, Naltrexone reduces self-injury and improves learning, Exp. Clin. Psychopharmacol., 1, 242, 10.1037/1064-1297.1.1-4.242 Willemsen-Swinkels, 1999, Brief report: six months continuation treatment in naltrexone-responsive children with autism: an open-label case-control design, J. Autism Dev. Disabil., 29, 167, 10.1023/A:1023000929040 White, 2000, Naltrexone treatment for a 3-year-old boy with self-injurious behavior, Am. J. Psychiatry, 157, 1574, 10.1176/appi.ajp.157.10.1574 Sandman, 1998, Opiate blockers, 291 Sandman, 1990, The opiate hypothesis in autism and self-injury, J. Child Adolesc. Psychopharmacol., 1, 235, 10.1089/cap.1990.1.237 Sandman, 1988, B-endorphin disregulation in autistic and self-injurious behavior: a neurodevelopmental hypothesis, Synapse, 2, 193, 10.1002/syn.890020304 Cataldo, 1982, The biological basis for self-injury in the mentally retarded, Anal. Intervent. Dev. Disabil., 2, 21, 10.1016/0270-4684(82)90004-0 Deutsch, 1986, Rationale for the administration of opiate antagonists in treating infantile autism, Am. J. Ment. Retard., 90, 631 Farber, 1987, Psychopharmacology of self-injurious behavior in the mentally retarded, J. Am. Acad. Child Adolesc. Psych., 26, 296, 10.1097/00004583-198705000-00002 Davidson, 1993, Effects of naloxene of self-injurious behavior: a case study, Appl. Res. Ment. Retard., 4, 1, 10.1016/S0270-3092(83)80013-7 Sandman, 1983, Naloxone attenuates self-abusive behavior in developmentally disabled clients, Appl. Res. Ment. Retard., 4, 5, 10.1016/S0270-3092(83)80014-9 Scifo, 1996, Opioid–immune interactions in autism: behavioural and immunological assessment during a double-blind treatment with naltrexone, Ann. Ist. Super. Sanitá, 32, 351 Willemsen-Swinkles, 1995, Failure of naltrexone to reduce self-injurious and autistic behavior in mentally retarded adults, Arch. Gen. Psychiatry, 52, 766, 10.1001/archpsyc.1995.03950210060011 Sandman, 2000, Long-term effects of naltrexone on self-injurious behavior, Am. J. Ment. Retard., 105, 103, 10.1352/0895-8017(2000)105<0103:LEONOS>2.0.CO;2 Thompson, 2000 Rodbard, 1978, Improved curve fitting, parallelism testing, characterization of sensitivity and specificity, validation and optimization for radioligand assays, Radioimmunoassay Relat. Proced. Med., 1, 469